


**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail Label No. EV381798422US in an envelope addressed to: MS Patent Application, Commissioner for Patents, Alexandria, VA 22313, on March 15, 2004.

  
Valerie Cohen

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Gustavo A. MOVIGLIA

Serial No.: Not Yet Assigned

Filing Date: Concurrently Herewith

For: TUMOR /B-CELL HYBRID CELLS  
AND USES THEREOF

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97**

MS Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☒ **With the application; accordingly, no fee or separate requirements are required.**
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **545872000100**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 15, 2004

Respectfully submitted,

By:   
Otis Littlefield  
Registration No. 48,751

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California 94105-2482  
Telephone: (415) 268-6846  
Facsimile: (415) 268-7522

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 54587200100	Application Number Not Yet Assigned
	Applicant  Gustavo A. MOVIGLIA	
	Filing Date Concurrently Herewith	Group Art Unit Not Yet Assigned
	Mailing Date March 15, 2004	

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	04/03/2001	6,210,662	Laus et al.			
	2.	04/04/1998	5,597,312	Murphy et al.			
	3.	04/11/2002	US 2002/0041868 A1	Nicolette et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	4.	08/16/2001	01/59073	WO			
	5.	10/22/1998	98/46785	WO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	6.	Gong, J. et al. (2000). "Selection and Characterization of MUC1-Specific CD8 <sup>+</sup> T Cells from MUC1 Transgenic Mice Immunized with Dendritic-Carcinoma Fusion Cells." <i>Immunology</i> , 101:316-324.
	7.	Li, J. et al. (2001). "Purified Hybrid Cells from Dendritic Cell and Tumor Cell Fusions are Superior Activators of Antitumor Immunity." <i>Cancer Immunol Immunother</i> 50: 456-462.
	8.	Tanaka, Y. et al. (2001). "Vaccination with Allogenic Dendritic Cells Fused to Carcinoma Cells Induces Antitumor Immunity in MUC1 Transgenic Mice." <i>Clinical Immunology</i> Vol. 101, No. 2, pp. 192-200.
	9.	Guo, Y. et al. (1994). "Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells." <i>Science</i> , 263: 518-520.
	10.	Valone F. H. et al. (2001). "Dendritic Cell-Based Treatment of Cancer: Closing in on a Cellular Therapy." <i>The Cancer Journal</i> , 7: S53-S61.
	11.	Moviglia, G. A. (1996). "Development of Tumor B-Cell Lymphocyte Hybridoma (TBH) Autovaccination. Results of a Phase I-II Clinical Trial." <i>Transfus. Sci.</i> , Vol 17, No. 4, pp. 643-649.
	12.	Hersey P. et al. (2004). "Phase I/II Study of Treatment with Dendritic Cell Vaccines in Patients with Disseminated Melanoma." <i>Cancer Immunol Immunother</i> , 53: 125-134.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 54587200100	Application Number Not Yet Assigned
	Applicant  Gustavo A. MOVIGLIA	
	Filing Date Concurrently Herewith	Group Art Unit Not Yet Assigned
	Mailing Date March 15, 2004	

13.	Moviglia G. A. et al. (2000). "Dendritic Cells Preparation for Cancer Treatment." <i>Journal of Clinical Apheresis</i> 15:187. Abstracts of the 21 <sup>st</sup> Annual Meeting of the American Society for Apheresis.
14.	Moviglia, G. A. (04/17/02). "Dendritic Cells Preparation for Cancer Treatment." 26 pages. Located at <a href="http://www.santojanni.org.ar/hemoterapia/Dc1/">http://www.santojanni.org.ar/hemoterapia/Dc1/</a> printed on 3/12/04.
15.	Gong, J. et al. (1997). "Induction of Antitumor Activity by Immunization with Fusions of Dendritic and Carcinoma Cells." <i>Nature Medicine</i> , Vol. 3, No. 5, pp. 558-561.
16.	Grabbe, S. et al. (1995). "Dendritic Cells as Initiators of Tumor Immune Responses: A Possible Strategy for Tumor Immunotherapy." <i>Immunology Today</i> , Vol. 16, No. 3, pp. 117-121.
17.	Timmerman, J. & Levy, R. (1999). Dendritic Cell Vaccines for Cancer Immunotherapy." <i>Annu. Rev. Med</i> , 50: 507-529.
18.	Qin, Z. et al. (1998). "B Cells Inhibit Induction of T Cell-Dependent Tumor Immunity." <i>Nature Medicine</i> , Vol. 4, No.5, pp. 627-630.
19.	Wu, S. (1998). "Treatment of Hepatocellular Carcinoma with the Cellular Tumor Vaccines Generated by <i>In Vitro</i> Modification of Tumor Cells with Non Gene Transfer Approaches." <i>Gene Therapy of Cancer</i> , pp. 283-293.
20.	Gong, J. et al. (2000). Fusions of Human Ovarian Cells with Autologous or Allogenic Dendritic Cells Induce Antitumor Immunity." <i>The Journal of Immunology</i> , 165: 1705-1711.
21.	Celluzzi, C. M. & Falo, L. D. Jr. (1998). "Cutting Edge: Physical Edge: Physical Interaction between Dendritic Cells and Tumor Cells Results in an Immunogen that Induces Protective and Therapeutic Tumor Rejection." <i>The Journal of Immunology</i> , 160: 3081-3085.
22.	Surman, D. R. et al. (2000). "Cutting Edge: CD4 <sup>+</sup> T Cell Control of CD8 <sup>+</sup> T Cell Reactivity to a Model Tumor Antigen." <i>The Journal of Immunology</i> , 164: 562-565.
23.	Wang, J. et al. (1998). "Eliciting T Cell Immunity Against Poorly Immunogenic Tumors by Immunization with Dendritic Cell-Tumor Fusion Vaccines." <i>The Journal of Immunology</i> , 161: 5516-5524.
24.	Strome, S. E. et al. (2002). Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response." <i>Cancer Research</i> , 62: 1884-1889.
25.	Morse, M. A. et al. (1999). "Migration of Human Dendritic Cells after Injection in Patients with Metastatic Malignancies." <i>Cancer Research</i> , 59: 56-58.
26.	Gong, J. et al. (2001). "Immunization Against Murine Multiple Myeloma with Fusions of Dendritic and Plasmacytoma Cells is Potentiated by Interleukin 12." <i>Immunology</i> , Vol. 99, No. 7, pp. 2512-2517.
27.	Gong, J. et al. (2000). "Activation of Antitumor Cytotoxic T Lymphocytes by Fusions of Human Dendritic Cells and Breast Carcinoma Cells." <i>Immunology</i> , Vol. 97, No. 6, pp. 2715-2718.
28.	Homma, S. et al. (2001). "Preventive Antitumor Activity Against Hepatocellular Carcinoma (HCC) Induced by Immunization with Fusions of Dendritic Cells and HCC Cells in Mice." 36: 764-771.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	